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Open access under CC BYThe pancreatic zymogen granule membrane protein (GP2) is expressed by pancreatic acinar cells and M
cells of the ileum. GP2 is the closest related homologue of the urine resident Tamm–Horsfall protein
(THP). Recently, it was shown that THP is a ligand of various scavenger receptors (SRs). Therefore, we
were interested, if GP2 has similar properties.
cDNA of different SRs was stably transfected into a murine thymoma cell line. GP2 was recombinantly
expressed, puriﬁed and biotinylated. Binding or uptake of GP2 by transfected cells or monocyte-derived
dendritic cells (moDCs) was analyzed by ﬂow-cytometry.
GP2 is a binding partner of the scavenger receptor expressed on endothelial cells I (SREC-I) but not of
SR-AI and SR-BI. The dissociation constant (Kd) of GP2 binding to SREC-I is 41.3 nM. SREC transfected cells
are able to internalize GP2. moDCs express SREC-I and also bind and internalize GP2. Inhibition of SREC-I
on moDCs with anti-SREC-I antibodies does not result in a decreased GP2 binding.
Interaction of GP2 with SREC-I and uptake might have profound effects in antigen clearance and medi-
ation of the immune response. In addition to SREC-I other presently unknown receptors for GP2 on DCs
might be involved in this process.
 2010 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
The pancreatic zymogen granule membrane protein 2 (GP2) is
the most abundant membrane glycoprotein in the zymogen gran-
ules of the pancreatic acinar cells [1,2], and has been discussed
to play a role in the formation and the secretion of these granules
[3–5]. In addition, GP2 is expressed on the apical surface of intes-
tinal M cells and appears to be overexpressed in colon biopsies of
Crohn’s disease patients [19]. It was demonstrated that membrane
resident GP2 is capable of binding pathogenic Escherichia coli.
Bacterial binding to GP2 mediated the transcytosis of the patho-
gens through M cells. This resulted in the preferential formation
of IgA antibodies and the establishment of a mucosal immunity [6].
GP2 is the closest related homologue of the Tamm–Horsfall Pro-
tein (THP), which is exclusively expressed in the urogenital tract.
Both proteins show 52% identity and 85% similarity in their amino
acid sequence and might have evolved from gene duplication [7,8].
Like THP, GP2 has a zona pelucida domain and is linked to the api-.at (G.J. Zlabinger).
-NC-ND license.cal epithelium via a glycosyl phosphatidyl inositol (GPI) anchor
[9,10]. Since both proteins exist also in soluble form, it is supposed
that a phenylalanine speciﬁc protease mediates the cleavage from
the membrane [11]. GP2 and THP have the ability to attach to the
FimH adhesin of E. coli or Salmonella typhimurium. Binding to E. coli
is dependent on the glycosylation status, and in particular on the
presence of mannose residues [12,13]. Whereas soluble THP is con-
sidered to be a decoy receptor in the urogenital tract that inhibits
the adherence of uropathogenic bacteria, the functional role of sol-
uble GP2 is still unclear.
Scavenger receptors represent a highly heterogenic group of
membrane receptors. These molecules are described to have func-
tions in the binding of modiﬁed low density lipoproteins (LDL) as
well as the recognition and uptake of pathogens [14]. The scavenger
receptor expressed on endothelial cells I (SREC-I) is expressed by
various cell types, as for example dendritic cells (DCs) [15]. SREC-I
mediates the binding and internalization of several proteins, as for
example acetylated LDL (acLDL) and heat shock protein (HSP) 90
[16]. Recently, it has been demonstrated that SREC-I is involved in
processes that contribute to cross presentation. Murshid et al.
showed that HSP90 coupled ovalbumin peptides were taken up by
SREC-I and efﬁciently presented to a peptide speciﬁc CD8(+) T-cell
hybridoma cell line [17]. Furthermore, it has been demonstrated
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urinary protein which is considered to play a role in several immu-
nological processes [18].
In the present study we show for the ﬁrst time that GP2 is a
high afﬁnity interaction partner of SREC-I. Moreover, we demon-
strate that GP2 can be internalized by SREC-I expressing cell lines.
Furthermore, DCs are capable to bind and to take up GP2.2. Material and methods
2.1. Reagents
All chemicals were of American Chemical Society reagent grade
and were purchased from SigmaAldrich (Deisenhofen, Germany)
unless stated otherwise. Phycoerythrin (PE) conjugated SR-AI anti-
bodies and biotinylated goat anti-human SREC-I antibodies were
purchased from R&D Systems (Minneapolis, MN). Unbiotinylated
mouse anti-human SREC-I monoclonal antibodies (AK 503) were
a kind gift of Prof. Otto Majdic (Institute of Immunology, Medical
University of Vienna, Austria). Mouse anti-human SR-BI antibodies
were obtained from BD Biosciences (San Jose, CA). Alexa Fluor 488
acLDL (acLDL-488) was purchased from Invitrogen (Carlsbad, CA).
Lymphoprep was obtained from Axis Shield (Oslo, Norway).
Paramagnetic CD14 beads were purchased from Miltenyi (Bergisch
Gladbach, Germany). IL-4 and GM-CSF were obtained from
PeproTech (Rocky Hill, NJ). Streptavidin-PE (SA-PE) and goat
anti-mouse (GaM) IgG-PE were purchased from Jackson Immuno-
Research (West Grove, PA). RPMI 1640 supplemented with 10%
fetal calf serum (FCS), glutamine and penicillin/streptomycin was
used as cell culture medium (all from PAA, Pasching, Austria).2.2. Expression and puriﬁcation of GP2
Expression of GP2 has been described in detail elsewhere [19].
In brief, cDNA of the GP2 isoform BAA88166 (pancreatic zymogen
granule membrane associated protein GP2 alpha form) was in-
serted into a pVL1393-vector. 2.5 lg BaculoGold (BD) and 2.5 lg
DNA of the insert containing vector were mixed with H2O and
Polyfect transfection reagent (Qiagen, Hilden, Germany). Pre-
pared Sf9 cells were incubated for 5 days with the solution. For
infection, Sf9 cells were incubated with the supernatant of the
previous infected culture in a 1:10 ratio for 3 days. GP2 producing
Sf9 were harvested and lysed in non denaturating lysis buffer
supplemented with a protease inhibitor cocktail (Roche, Mann-
heim, Germany). GP2 was isolated employing an equilibrated
Ni-chelate column, followed by anion exchange chromatography
(both types of columns were purchased from GE Healthcare,
Buckinghamshire, GB). GP2 was biotinylated (GP2-bio) using
standard procedures.2.3. Generation of SR expressing Bw cells
The coding sequences of human SREC-I, SR-AI, SR-BI were PCR-
ampliﬁed from a cDNA expression library generated from human
DC using appropriate primers containing restriction endonuclease
recognition sites. The PCR products were cloned into the retroviral
expression vector pBMN [20]. The integrity of the resulting retrovi-
ral expression constructs was conﬁrmed by DNA sequencing. The
murine thymoma cell line Bw5147 (referred to as Bw cells
throughout this work) was then transduced retrovirally with
pBMN plasmids encoding either SREC-I, SR-AI or SR-BI. For control
purposes, a vector containing the lacZ gene was used (pBMN-Z)
[21]. Bw cells were cultured in medium supplemented with
plasmocin and amphotericin B (PAA).2.4. Generation of monocyte-derived DCs (moDCs)
Buffy coats from healthy blood donors were obtained from the
Austrian Red Cross, where donors are adequately informed and the
procedure follows the ethical guidelines according to the declara-
tion of Helsinki. Blood was diluted 1:2 with phosphate buffered
saline (PBS; PAA). PBMCs were isolated by density gradient centri-
fugation. Monocytes were isolated by magnetic cell sorting. moDCs
were generated by incubating monocytes in culture medium sup-
plemented with 10 ng/mL IL-4 and 50 ng/mL GM-CSF for 6 days.
2.5. Binding studies and internalization assays
Binding experiments using GP2-bio were performed in PBS sup-
plemented with 0.5% bovine serum albumin (PBS-B). GP2-bio was
detected using SA-PE, diluted 1:200 in PBS-B. For afﬁnity measure-
ments Bw-SREC-I cells were incubated with deﬁned concentrations
of GP2-bio dissolved in PBS-B for 40 min at 4 C, washed twice and
then stained with SA-PE. For uptake experiments, Bw-SREC-I were
incubated with 10 lL GP2-bio at a concentration of 10 lg/mL in
PBS-B for 20 min at 4 C. Cells were washed twice with PBS-B
and incubated with SA-PE (group 1) or PBS-B (group 2). Subse-
quently, cells were washed in culture medium and incubated at
37 C for 60 min. Cells were washed with ice-cold PBS-B and then
incubated with PBS-B (group 1) or stained with SA-PE (group 2).
Flow cytometric analysis was performed using a BD FacsCalibur
(BD Biosciences).3. Results
3.1. GP2 binds to SREC-I
Retrovirally transduced Bw cells were evaluated for the expres-
sion of SRs by ﬂow cytometry using SR speciﬁc antibodies. SR-AI,
SR-BI and SREC-I were expressed on the surface of the respective
Bw-clones at high levels (Fig. 1). To address whether SRs can bind
their genuine ligand, SR expressing Bw clones were incubated with
acLDL-488. All SR expressing clones but not mock transfected Bw
cells strongly bound acLDL-488 (Fig. 1) and were therefore consid-
ered to be functional. Subsequently, SR expressing Bw clones were
incubated with GP2-bio, which strongly bound to clones express-
ing SREC-I. No binding was observed with SR-AI or SR-BI or mock
transfected Bw cells (Fig. 1). These results clearly identify SREC-I
as a cellular receptor for GP2.
3.2. Determination of equilibrium Kd of the SREC-I - GP2 Interaction
Since GP2 clearly bound to cells expressing SREC-I, it was of
interest to assess the afﬁnity of this interaction. Therefore, SREC-I
expressing cells were incubated with increasing amounts of GP2,
resulting in an increased binding of the ligand (Fig. 2A).
By blotting the inverted values of the resulting MFI against the
concentration of GP2, a Lineweaver–Burk diagram was generated,
which delivered a regression line of y = 0.581x + 0.014 and an
intercept of the x-axis at 0.025 ± 0.0029 1/nM (Fig. 2B). This al-
lowed the calculation of the equilibrium Kd, which is 41.3 ±
5.06 nM. The data sets exhibited a strong correlation (R2 = 0.929).
3.3. Internalization of GP2 by Bw-SREC-I cells and moDCs
Since SREC-I has been shown to be a receptor with endocytic
capacity [22], wewere interestedwhetherGP2 is takenup after liga-
tion. Therefore Bw-SREC-I cells were incubatedwith GP2-bio at 4 C
and washed. SA-PE staining of the cells was either performed after
the washing step or following a one hour incubation step at 37 C.
Fig. 1. SR expression and binding to acLDL-488 and GP2-bio by transduced Bw cells. SR expressing Bw cells were stained with PE-labeled antibodies (Bw-SR-AI), biotinylated
antibodies (Bw-SREC-I) or unlabeled antibodies (Bw-SR-BI). Binding of primary antibodies was detected with appropriate PE-labeled secondary reagents (left panel, bold
line). acLDL-488 was tested for its binding to SR expressing clones (middle panel, bold line). GP2-bio was incubated with SR expressing Bw clones and stained with SA-PE
(right panel, bold line). Mock transfected Bw cells were used as control in all binding experiments (thin lines). The depicted results are representative for three independent
experiments. MFI = mean ﬂuorescence intensity.
Fig. 2. Determination of the binding afﬁnity of GP2 for SREC-I (A) Bw cells expressing SREC were incubated with indicated concentrations of GP2-bio and stained with SA-PE.
(B) Inverted values of MFI and concentrations were used to create a Lineweaver–Burk diagram (right panel). Kd = 1/X(y0). MFI = Mean ﬂuorescence intensity. Error bars
indicate the standard error of the mean (n = 3).
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accessible for binding of SA-PE, whereas immediate application of
the secondary reagent and subsequent incubation for one hour at
37 C still resulted in a strong ﬂuorescence signal (Fig. 3A). These re-
sults clearly demonstrate efﬁcient endocytic uptake of GP2 by the
Bw-SREC-I cells. moDCs have been shown to bind and internalize
the GP2 homologue THP [23]. Therefore, we were also interested
to test the interaction of GP2 with this cell type. moDCs were able
to bind (Fig. 3B) and to internalize GP2-bio (Fig. 3C). Using the same
approach as described before, we found that moDCs stained with
SA-PE before the one hour incubation step retained surface staining
with GP2-bio. In contrast, staining after incubation at 37 C for one
hour resulted in a complete loss of SA-PE binding, indicating uptake
of GP2.3.4. Redundant GP2 binding structures on moDCs
In order to evaluate moDCs for the presence of additional GP2
binding receptors, we investigated the contribution of SREC-I on
the total GP2 binding. Therefore, we used anti-SREC-I antibodies
to block the interaction of moDCs with GP2-bio. Ligation of
SREC-I on SREC-I expressing Bw cells by speciﬁc antibodies re-
sulted in a strong decrease of the MFI, indicating that the antibod-
ies are suitable competitors of GP2 binding (Fig. 4A). In Fig. 4B
expression of SREC-I on the surface of moDCs is demonstrated.
By performing the inhibition experiments as shown in Fig. 4A for
SREC-I expressing Bw cells, however, no decrease in GP2-bio bind-
ing to moDCs could be observed (Fig. 4C). This indicates the pres-
ence of additional GP2 binding structures on these cells.
Fig. 3. Endocytosis of GP2-bio after binding to Bw-SREC or moDCs (A) SREC-I expressing Bw cells were incubated with 5 lg/mL GP2-bio. Cells were stained with SA-PE before
(bold line) or after a one-hour incubation step (grey histogram). For control, untransfected Bw cells were incubated with GP2-bio and stained with SA-PE before the one hour
incubation step (thin line). (B) moDCs were stained with 5 lg/mL GP2-bio and stained with SA-PE (bold line) or secondary reagent only (thin line). (C) To assess the
internalization of GP2, moDCs were incubated with GP2-bio. Cells were stained with SA-PE before (bold line) or after a one hour incubation step at 37 C (grey histogram). For
control, moDCs were stained with SA-PE (thin line). MFI = Mean ﬂuorescence intensity. One representative result of four independently performed experiments is shown.
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GP2 and THP are highly homologous proteins that share several
important features. They have a high sequence homology and can
attach to the FimH adhesin of E. coli or S. typhimurium. Further-
more, both molecules can be secreted from their producer cells
after cleavage of their GPI anchor and are then found in the excre-
tions of the gastrointestinal and urogenital tract, respectively [9].
Because of these profound similarities, we were interested,
whether membrane-detached GP2 and THP utilize common recep-
tors and thus analyzed the interaction of GP2 with SRs.
We here demonstrate that GP2 binds to SREC-I with an afﬁnity
of 41.3 nM. This resembles the dissociation constant of THP for
SREC-I, which was 16.8 nM [23]. Whereas THP was also shown to
bind SR-AI and SR-BI, speciﬁc interaction of these SRs with GP2
was not observed. Several reasons might be responsible for the dif-
ferences in the binding behavior. Despite the high sequence
homology with THP, GP2 lacks the epidermal growth factor like do-
mains [24], which could explain the lack of binding to SR-AI and
SR-BI. Furthermore, GP2 used in the present study was expressed
by Sf9 insect cells. Therefore also differences in glycosylation might
cause the absence of binding to these receptors [25].
SRs have an important function in the binding and uptake of
proteins. SREC-I, for example, has been described to bind and inter-
nalize acLDL as well as members of the heat shock protein (HSP)
family [22,26]. Recently, it has been revealed that also the urinary
glycoprotein THP is taken up by SREC-I [23]. Therefore, we were
interested whether SREC-I retrovirally expressed on the Bw cell
line also can mediate the internalization of GP2. By employing
internalization assays we demonstrated that bound GP2 disap-
peared from the surface of SREC-I expressing cells. We could alsoshow efﬁcient uptake of GP in moDCs. Although SREC-I is ex-
pressed on the surface of moDCs, we found that GP2 binding to
moDCs cannot be blocked by anti-SREC-I antibodies. These ﬁndings
indicate the presence of additional GP2 binding structures on DCs.
Thus, screening of receptors represented in a DC cDNA library and
expressed in special cell lines with GP2 as ligand might help to dis-
cover additional GP2 binding structures.
Recently, membrane resident GP2 was shown to mediate path-
ogen binding of enteropathogenic E. coli [12]. Binding of entero-
pathogenic E. coli by GP2 expressed on intestinal M-cells of the
ileum resulted in transcytosis of bacteria and the induction of a
mucosal immune response [6]. However, a physiological role of
soluble GP2 in host defense has not been reported to date. Based
on our ﬁndings, it can be speculated that binding and ingestion
of soluble GP2 bound to proteins or pathogens might also be an
important determinant in various immunological processes. A
model for the internalization of molecules by DCs via SREC-I was
recently provided by Murshid et al. The authors observed that
SREC-I, expressed on DCs bound and internalized complexes exist-
ing of HSP90 and ovalbumin (OVA) [17]. OVA peptides that did not
require processing were directly loaded on MHC class I and medi-
ated efﬁcient cross presentation by the antigen presenting cells. It
is well conceivable that GP2 also could act as a chaperone that en-
ables the uptake of proteins or peptides via SREC-I. The identiﬁca-
tion of proteins or peptides that bind to GP2 will help to clarify,
whether GP2 might play a role in immunological processes, as
for example cross presentation.
Interestingly, after secretion of pancreatic acinar cells, GP2 is
not digested by zymogens. Therefore, it could also function as a de-
coy receptor that inhibits the adhesion of potential pathogenic bac-
teria to the intestinal epithelium. This function has already been
Fig. 4. GP2-bio binding on moDCs cannot be inhibited by anti-SREC-I antibodies. (A) GP2-bio binding to SREC-I expressing Bw cells was inhibited by coincubating GP2-bio at
a concentration of 5 lg/mL with anti-SREC-I antibody at a concentration of 20 lg/mL (grey histogram). (B) Expression of SREC-I on moDCs cells was evaluated by staining
cells with biotinylated SREC-I antibody at a concentration of 20 lg/mL (bold line). (C) Inhibition of GP2-bio binding to moDCs by SREC-I antibodies was investigated by
coincubating moDCs with anti-SREC-I antibodies at a concentration of 20 lg/mL and GP2-bio at a concentration of 5 lg/mL (grey histogram). One representative result of
three independently performed experiments is shown. MFI = Mean ﬂuorescence intensity.
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uroplakin receptors by covering uropathogenic E. coli [13]. Further-
more, GP2 could act as a bridge that mediates microbial binding to
SR expressing immune cells. Opsonization of microbes with solu-
ble GP2 would thus facilitate their uptake by phagocytic cells of
the immune system. Such interaction of local substances with res-
ident cells of the immune system should be suitable to draw the
attention of the immune system to local invaders so that it be-
comes well prepared in case these microbes indeed get access to
local tissues.
In conclusion, the present study reveals GP2 as a novel high
afﬁnity interaction partner of SREC-I. Further investigations will
be necessary to unravel the possible implications of this recep-
tor/ligand interaction on physiological processes, as for example
infection and inﬂammation.5. Disclosures
GA Generic Assays GmbH (D Ro) is a manufacturer and distrib-
utor of in vitro diagnostics. All remaining authors have no compet-
ing ﬁnancial interests.Acknowledgments
The project was funded by the Austrian Science Foundation
(FWF) grant P20508-B11. We thank Claus Wenhardt and
Margarethe Merio for the excellent technical assistance. We thank
Prof. Otto Majdic for providing us with SREC-I monoclonal
antibodies.References
[1] S. Fukuoka, Analysis of ZAPs, zymogen granule membrane associated proteins,
in the regulated exocytosis of the pancreas, Biosci. Biotechnol. Biochem. 58
(1994) 1282–1285.
[2] R.A. Ronzio, K.E. Kronquist, D.S. Lewis, R.J. MacDonald, S.H. Mohrlok, J.J.
O’Donnell Jr., Glycoprotein synthesis in the adult rat pancreas. IV. Subcellular
distribution of membrane glycoproteins, Biochim. Biophys. Acta 508 (1978)
65–84.
[3] K. Schmidt, H. Dartsch, D. Linder, H.F. Kern, R. Kleene, A submembranous
matrix of proteoglycans on zymogen granule membranes is involved in
granule formation in rat pancreatic acinar cells, J. Cell Sci. 113 (Pt12) (2000)
2233–2242.
[4] K. Schmidt, M. Schrader, H.F. Kern, R. Kleene, Regulated apical secretion of
zymogens in rat pancreas. Involvement of the glycosylphosphatidylinositol-
anchored glycoprotein GP-2, the lectin ZG16p, and cholesterol-glycosphin-
golipid-enriched microdomains, J. Biol. Chem. 276 (2001) 14315–14323.
[5] S. Yu, S.A. Michie, A.W. Lowe, Absence of the major zymogen granule
membrane protein, GP2, does not affect pancreatic morphology or secretion,
J. Biol. Chem. 279 (2004) 50274–50279.
[6] K. Hase, K. Kawano, T. Nochi, G.S. Pontes, S. Fukuda, M. Ebisawa, K. Kadokura, T.
Tobe, Y. Fujimura, S. Kawano, A. Yabashi, S. Waguri, G. Nakato, S. Kimura, T.
Murakami, M. Iimura, K. Hamura, S. Fukuoka, A.W. Lowe, K. Itoh, H. Kiyono, H.
Ohno, Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates
mucosal immune response, Nature 462 (2009) 226–230.
[7] K. Kobayashi, K. Yanagihara, K. Ishiguro, S. Fukuoka, GP2/THP gene family of
self-binding, GPI-anchored proteins forms a cluster at chromosome 7F1 region
in mouse genome, Biochem. Biophys. Res. Commun. 322 (2004) 659–664.
[8] T.C. Hoops, M.J. Rindler, Isolation of the cDNA encoding glycoprotein-2 (GP-2),
the major zymogen granule membrane protein. Homology to uromodulin/
Tamm–Horsfall protein, J. Biol. Chem. 266 (1991) 4257–4263.
[9] F. Seraﬁni-Cessi, N. Malagolini, D. Cavallone, Tamm–Horsfall glycoprotein:
Biology and clinical relevance, Am. J. Kidney Dis. 42 (2003) 658–676.
[10] M.J. Rindler, S.S. Naik, N. Li, T.C. Hoops, M.N. Peraldi, Uromodulin
(Tamm–Horsfall glycoprotein/uromucoid) is a phosphatidylinositol-linked
membrane protein, J. Biol. Chem. 265 (1990) 20784–20789.
[11] S. Fukuoka, K. Kobayashi, Analysis of the C-terminal structure of urinary
Tamm–Horsfall protein reveals that the release of the glycosyl
phosphatidylinositol-anchored counterpart from the kidney occurs by
M.A. Hölzl et al. / Cellular Immunology 267 (2011) 88–93 93phenylalanine-speciﬁc proteolysis, Biochem. Biophys. Res. Commun. 289
(2001) 1044–1048.
[12] S. Yu, A.W. Lowe, The pancreatic zymogen granule membrane protein,
GP2, binds Escherichia coli Type 1 ﬁmbriae, BMC Gastroenterol. 9 (2009)
58.
[13] J. Pak, Y. Pu, Z.T. Zhang, D.L. Hasty, X.R. Wu, Tamm–Horsfall protein binds to
type 1 ﬁmbriated Escherichia coli and prevents E. Coli from binding to uroplakin
Ia and Ib receptors, J. Biol. Chem. 276 (2001) 9924–9930.
[14] T. Areschoug, S. Gordon, Pattern recognition receptors and their role in innate
immunity: Focus on microbial protein ligands, Contrib. Microbiol. 15 (2008)
45–60.
[15] C. Beauvillain, F. Meloni, J.C. Sirard, S. Blanchard, U. Jarry, M. Scotet,
G. Magistrelli, Y. Delneste, V. Barnaba, P. Jeannin, The scavenger receptors
SRA-1 and SREC-I cooperate with TLR2 in the recognition of the hepatitis C
virus non-structural protein 3 by dendritic cells, J. Hepatol. 52 (2010) 644–
651.
[16] H. Adachi, M. Tsujimoto, H. Arai, K. Inoue, Expression cloning of a novel
scavenger receptor from human endothelial cells, J. Biol. Chem. 272 (1997)
31217–31220.
[17] A. Murshid, J. Gong, S.K. Calderwood, Heat shock protein 90 mediates efﬁcient
antigen cross presentation through the scavenger receptor expressed by
endothelial cells-I, J. Immunol. 195 (2010) 2903–2917.
[18] M.A. Holzl, J. Hofer, P. Steinberger, K. Pﬁstershammer, G.J. Zlabinger, Host
antimicrobial proteins as endogenous immunomodulators, Immunol. Lett. 119
(2008) 4–11.
[19] D. Roggenbuck, G. Hausdorf, L. Martinez-Gamboa, D. Reinhold, T. Buttner,
P.R. Jungblut, T. Porstmann, M.W. Laass, J. Henker, C. Buning, E. Feist,
K. Conrad, Identiﬁcation of GP2, the major zymogen granule membraneglycoprotein, as the autoantigen of pancreatic antibodies in Crohn’s disease,
Gut 58 (2009) 1620–1628.
[20] Y. Hitoshi, J. Lorens, S.I. Kitada, J. Fisher, M. LaBarge, H.Z. Ring, U. Francke,
J.C. Reed, S. Kinoshita, G.P. Nolan, Toso, a cell surface, speciﬁc regulator of Fas-
induced apoptosis in T cells, Immunity 8 (1998) 461–471.
[21] P. Steinberger, O. Majdic, S.V. Derdak, K. Pﬁstershammer, S. Kirchberger,
C. Klauser, G. Zlabinger, W.F. Pickl, J. Stockl, W. Knapp, Molecular
characterization of human 4Ig-B7–H3, a member of the B7 family with four
Ig-like domains, J. Immunol. 172 (2004) 2352–2359.
[22] Y. Tamura, J. Osuga, H. Adachi, R. Tozawa, Y. Takanezawa, K. Ohashi, N. Yahagi,
M. Sekiya, H. Okazaki, S. Tomita, Y. Iizuka, H. Koizumi, T. Inaba, H. Yagyu,
N. Kamada, H. Suzuki, H. Shimano, T. Kadowaki, M. Tsujimoto, H. Arai, N.
Yamada, S. Ishibashi, Scavenger receptor expressed by endothelial cells I
(SREC-I) mediates the uptake of acetylated low density lipoproteins by
macrophages stimulated with lipopolysaccharide, J. Biol. Chem. 279 (2004)
30938–30944.
[23] K. Pﬁstershammer, C. Klauser, J. Leitner, J. Stockl, O. Majdic, T. Weichhart,
Y. Sobanov, V. Bochkov, M. Saemann, G. Zlabinger, P. Steinberger, Identiﬁcation
of the scavenger receptors SREC-I, Cla-1 (SR-BI), and SR-AI as cellular receptors
for Tamm–Horsfall protein, J. Leukoc. Biol. 83 (2008) 131–138.
[24] S.M. Wong, A.W. Lowe, Sequence of the cDNA encoding human GP-2, the
major membrane protein in the secretory granule of the exocrine pancreas,
Gene 171 (1996) 311–312.
[25] F. Altmann, E. Staudacher, I.B. Wilson, L. Marz, Insect cells as hosts for the
expression of recombinant glycoproteins, Glycoconj. J. 16 (1999) 109–123.
[26] J.G. Facciponte, X.Y. Wang, J.R. Subjeck, Hsp110 and Grp170, members of the
Hsp70 superfamily, bind to scavenger receptor-A and scavenger receptor
expressed by endothelial cells-I, Eur. J. Immunol. 37 (2007) 2268–2279.
